CD274 and melanoma: To investigate the timing of when PD-L1 expression changes and biological processes may occur during drug treatment, we investigated RNA-Seq data derived from two melanoma cell lines (M229 and M238) [5], which had been treated with an MAPK inhibitor, and for which RNA-Seq analysis was carried out at different time points between the initial resistance, generation of drug tolerance, and finally permanent acquired resistance.